Naphazoline + Pheniramine


Generic Medicine Info
Indications and Dosage
Ophthalmic
Allergic condition, ocular, Inflammatory condition, ocular
Adult: Available preparations:
Naphazoline HCl 0.25 mg and pheniramine 3 mg per mL of eye drop solution
Naphazoline HCl 0.1 mg and pheniramine 2.2 mg per mL of eye drop solution

Instil 1-2 drops in the affected eye(s) up to 4 times daily.
Contraindications
Narrow-angle glaucoma.
Special Precautions
Patient with CV disease, hypertension, diabetes mellitus, hyperthyroidism, benign prostatic hyperplasia, local infection or injury. Children and elderly. Pregnancy and lactation. Concomitant use with MAOIs.
Adverse Reactions
Significant: Eye irritation, light sensitivity (temporary), tingling sensation, rebound ocular vasodilation or congestion (prolonged or excessive use).
Eye disorders: Ocular discomfort, pupil dilatation, increased ocular pressure, mydriasis, keratitis, eye pain, ocular hyperaemia, mydriasis, blurred vision (temporary).
Patient Counseling Information
This drug may cause transient effect on vision, if affected, do not drive or operate machinery. Remove contact lenses prior to administration and reinsert after 15 minutes.
Overdosage
Symptoms (particularly in children): Depression of the CNS with marked reduction in body temperature and bradycardia, excessive sweating, drowsiness, and coma; hypertension followed by hypotension. Management: Symptomatic and supportive treatment.
Drug Interactions
Increased risk of severe hypertensive crisis with MAOIs. Enhanced therapeutic effect with TCAs.
Action
Description: Naphazoline is an α-adrenergic receptor agonist which causes vasoconstriction by stimulating arterioles of the conjunctiva thus reducing swelling, redness and discomfort.
Pheniramine is an alkylamine derivative which binds to histamine H1 receptors on conjunctival epithelial cells, thereby reducing ocular itching.
Onset: Conjunctival vasoconstriction: Within 10 minutes.
Duration: Up to 6 hours.
Pharmacokinetics:
Absorption: Pheniramine: Time to peak plasma concentration: 1-2.5 hours.
Metabolism: Pheniramine: Metabolised to N-desmethylpheniramine, and N-didesmethylpheniramine metabolites.
Excretion: Pheniramine: Via urine (70-83% as unchanged drug and metabolites). Elimination half-life: 16-19 hours.
Chemical Structure

Chemical Structure Image
Naphazoline

Source: National Center for Biotechnology Information. PubChem Database. Naphazoline, CID=4436, https://pubchem.ncbi.nlm.nih.gov/compound/Naphazoline (accessed on Jan. 22, 2020)


Chemical Structure Image
Pheniramine

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 4761, Pheniramine. https://pubchem.ncbi.nlm.nih.gov/compound/Pheniramine. Accessed Sept. 24, 2021.

Storage
Store between 15-25°C. Protect from light.
MIMS Class
Ophthalmic Decongestants, Anesthetics, Anti-Inflammatories
ATC Classification
S01GA51 - naphazoline, combinations ; Belongs to the class of sympathomimetics used as ophthalmologic decongestants.
References
Anon. Naphazoline (Ophthalmic). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 12/08/2021.

Anon. Naphazoline and Pheniramine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 12/08/2021.

Anon. Pheniramine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 12/08/2021.

Buckingham R (ed). Naphazoline. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 12/08/2021.

Buckingham R (ed). Pheniramine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 12/08/2021.

Celsus Naphazoline Hydrochloride + Pheniramine Maleate (Celsus Pharmaceuticals Phils., Inc.). MIMS Philippines. http://www.mims.com/philippines. Accessed 12/08/2021.

Naphazoline; Pheniramine. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com. Accessed 12/08/2021.

Naphcon A (Alcon Laboratories, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 12/08/2021.

Naphcon A (S.A. Alcon-Couvreur N.V.). MIMS Philippines. http://www.mims.com/philippines. Accessed 12/08/2021.

Opcon-A (Bausch & Lomb Incorporated). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 12/08/2021.

Visine Allergy Eye Relief Multi-Action (Johns on & Johns on Cons umer Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 12/08/2021.

Disclaimer: This information is independently developed by MIMS based on Naphazoline + Pheniramine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in